Metastatic renal cell carcinoma

10 trials 3 recruiting MedDRA PT
10 Registered trials
3 Recruiting
9 Unique sponsors
7 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 7
Mechanism of action (INN-stem analysis)
Kinase inhibitor 4 substances
Checkpoint inhibitor (PD-1) 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Phase III: 5 Phase II: 4 Phase I (First in Human): 1

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

5 trials
  • Bristol Myers Squibb International Corporation Commercial
    IPILIMUMAB; NIVOLUMAB; SUNITINIB
    2023-504761-23-00 13 countries 2014 n=578
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    CABOZANTINIB; IPILIMUMAB; NIVOLUMAB; SUNITINIB
    2023-509711-83-00 7 countries 2017 n=265
    Ended
  • Incyte Corp. Commercial
    PEMBROLIZUMAB; SUNITINIB
    2024-512016-22-00 1 country 2017 n=5
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-507294-18-00 7 countries 2016 n=269
    Ended
  • Centre Hospitalier Universitaire De Bordeaux Academic
    AXITINIB; CABOZANTINIB; LENVATINIB; NIVOLUMAB; PEMBROLIZUMAB
    2024-514644-93-00 1 country 2022 n=372
    Ended

Phase II

4 trials
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-505816-39-00 4 countries 2023 n=113
    Ended
  • Centre Leon Berard Academic
    PEMBROLIZUMAB
    2024-513986-38-00 1 country 2022 n=72
    Recruiting
  • Consorzio Oncotech Academic
    IMP not specified
    2024-511397-70-00 2 countries 2024 n=178
    Recruiting
  • Consorzio Oncotech Academic
    PEMBROLIZUMAB
    2024-512180-31-00 1 country 2025 n=81
    Ended

Phase I (First in Human)

1 trial
  • Oncorena AB Commercial
    IMP not specified
    2023-505605-16-00 4 countries 2024 n=105
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Consorzio Oncotech Academic 2 Phase II 1
F. Hoffmann-La Roche AG Commercial 1 Phase II 0
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 0
Incyte Corp. Commercial 1 Phase III 0
Merck Sharp & Dohme LLC Commercial 1 Phase III 0
Oncorena AB Commercial 1 Phase I (First in Human) 1
Centre Leon Berard Academic 1 Phase II 1
Centre Hospitalier Universitaire De Bordeaux Academic 1 Phase III 0
New trials by year
2022
2
2023
1
2024
2
2025
1
← All indication landscapes